Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$62,819.00-0.97%ETH$1,875.51-0.03%GOLD$4,407.10-0.30%OIL$81.72+0.58%
Smart Investors Daily
Sign InSign Up Free
CR

NASDAQ · CRBU

Caribou Biosciences, Inc.

Healthcare · Biotechnology

$1.61

Down-$0.09 (-5.29%)

Updated Aug 14, 2026, 10:09 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
173.35M
P/E ratio
-1.11
Dividend yield
0.00%
52-week range
$1.43 – $2.49
Volume
1.14M
Avg. volume
2.34M

Price performance

CRBU price history

1M range · 21 trading sessions · Daily adjusted prices

CRBU closed at $1.61 after 21 trading sessions, down 3.01% for the selected period.

Last close
$1.61
Period change
-3.01%
Period low
$1.46
Period high
$1.70
Daily close
View OHLC price history
CRBU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$1.72$1.72$1.60$1.611.14M
Aug 12, 2026$1.69$1.71$1.66$1.70717.44K
Aug 11, 2026$1.68$1.71$1.65$1.69995.21K
Aug 10, 2026$1.65$1.676$1.63$1.66760.17K
Aug 7, 2026$1.65$1.67$1.625$1.65806.04K
Aug 6, 2026$1.61$1.68$1.59$1.641.06M
Aug 5, 2026$1.59$1.66$1.58$1.611.12M
Aug 4, 2026$1.50$1.58$1.50$1.571.34M
Aug 3, 2026$1.47$1.50$1.425$1.501.39M
Jul 31, 2026$1.53$1.53$1.43$1.461.13M
Jul 30, 2026$1.48$1.525$1.45$1.51916.46K
Jul 29, 2026$1.50$1.51$1.44$1.471.3M
Jul 28, 2026$1.60$1.60$1.47$1.491.96M
Jul 27, 2026$1.60$1.65$1.58$1.59731.62K
Jul 24, 2026$1.62$1.64$1.57$1.57946.83K
Jul 23, 2026$1.62$1.65$1.60$1.63824.43K
Jul 22, 2026$1.65$1.67$1.63$1.661.02M
Jul 21, 2026$1.61$1.725$1.59$1.651.61M
Jul 20, 2026$1.64$1.67$1.59$1.621.15M
Jul 17, 2026$1.62$1.69$1.60$1.651.45M
Jul 16, 2026$1.70$1.72$1.64$1.661.84M

Latest CRBU news

The latest Smart Investors Daily articles mentioning CRBU.

Stock researchCompany · Overview

CRBU research

Overview

Company profile and research snapshot.

Company profile

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
CRBU recent ratings
DateFirmRatingTarget
May 11, 2026HC Wainwright & Co.Buy—
Apr 7, 2026HC Wainwright & Co.Buy—
Mar 9, 2026Evercore ISI GroupOutperform—
Feb 2, 2026Clear StreetBuy—
Nov 5, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jun 29, 2026

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By